Pain identified as dominant symptom in long Covid
Pain may be the most prevalent and severe symptom reported by individuals with long Covid, according to a new study led by UCL (University College London) researchers. The study,… read more.
Pain may be the most prevalent and severe symptom reported by individuals with long Covid, according to a new study led by UCL (University College London) researchers. The study,… read more.
Pfizer Inc. and BioNTech SE announced that the FDA has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (COVID-19 Vaccine, mRNA),… read more.
Moral distress is the psychological harm that arises when people are forced to witness or perform actions that clash with their moral values. It is a problem that… read more.
To the world’s public health authorities, Covid-19 would be either a deadly disease for some or a simple respiratory illness for most, its symptoms clearing up in just… read more.
AIM ImmunoTech Inc. announced positive topline results from the Company’s Phase II study evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the… read more.
The NHS must treat at least 10 per cent more non-emergency hospital cases a month if it is to successfully start reducing the hefty backlog caused by the… read more.
An unprecedented resurgence in invasive meningococcal disease followed the lifting of pandemic restrictions in France, according to a paper published in the Journal of Infection and Public Health… read more.
Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling… read more.
Junshi Biosciences has revealed the final results for its Covid-19 pill VV 116 (mindeudesivir hydrobromide), indicating its efficacy. The data, which was published in The Lancet Infectious Diseases… read more.
Researchers from a study of patients treated for acute COVID-19 report that virologic rebound takes place in about 20.8 percent of subjects treated with nirmatrelvir-ritonavir (N-R, Paxlovid) versus… read more.
Despite the Centers for Disease Control and Prevention warning this year will be potentially dangerous for respiratory illnesses, a third of Americans are not concerned about the threat,… read more.
Many frontline health care workers in the United States experienced food insecurity and other significant financial challenges during the COVID-19 pandemic, according to a recent study led by… read more.